Respiratory effects of epidural morphine and sufentanil in the absence and presence of chlordiazepoxide.

The experiments determined the ventilatory effects of epidurally injected morphine and sufentanil in rats in the absence and in the presence of chlordiazepoxide, a drug that may alleviate the effects of stress. Soon after administration of morphine as well as of sufentanil, ventilation was more profoundly depressed when rats had been pretreated with chlordiazepoxide. With chlordiazepoxide, respiratory depression after epidural injection of the longer acting and poorly lipid-soluble morphine could still be observed when analgesic activity had disappeared. The data are explained most parsimoniously by assuming that stress counteracts the respiratory effects of epidural opiates, and that late respiratory depression can occur in as much as the opiate continues to act at points of time when the effects of stress have disappeared.

Pharmacological analysis of hyperventilation in arthritic rats.

The study examined the validity of increased minute volume of ventilation as a measurement of chronic pain in arthritic rats. The opiates morphine and R 62 818 attenuated arthritic hyperventilation, but only at doses which also reduced the ventilatory response to CO2 in normal rats. The non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and suprofen, the corticosteroids, cortisone and dexamethasone, and the tranquillizers, haloperidol and chlordiazepoxide, were essentially ineffective except at doses that also produced anti-inflammatory and/or toxic effects. A combination of an in itself ineffective dose of R 62 818 with an ineffective dose of suprofen did attenuate arthritic hyperventilation, and the combination constituted the only pharmacological treatment that did so in the absence of anti-inflammatory, toxic or intrinsic respiratory effects. The data are consistent with the hypothesis that pain rather than acidosis mediates arthritic hyperventilation. They also suggest that combinations of an opiate with an NSAID may perhaps be effective in alleviating this pain.

Fatty acid profiles, antioxidant status, and growth of preterm infants fed diets without or with long-chain polyunsaturated fatty acids. A randomized clinical trial.

Long-chain polyunsaturated fatty acids (LCP) are considered conditionally essential nutrients for the infant born prematurely, and attempts are being made to match fatty acid profiles of formula and breast fed infants. In this double-blind, randomized study we investigated the effects of a formula enriched with both n-6 and n-3 LCP on plasma fatty acid profiles, antioxidant status and growth of premature infants. 29 infants received either a formula devoid of LCP or a LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat alpha-linolenic acid metabolites). 17 breast fed infants served as a control group. At study entry as well as two and four weeks later, plasma and urine samples were collected, growth data obtained and food tolerance was documented. At the end of the four week study period, plasma docosahexaenoic acid (DHA) levels of supplemented infants were significantly higher than those of unsupplemented infants and similar to those of infants fed human milk. Plasma n-6 LCP concentrations including arachidonic acid (AA) were similar between groups. The plasma alpha-tocopherol levels of breast fed and supplemented infants were similar and tended to be lower than in infants fed the formula devoid of LCP. Urinary malondialdehyde (MDA) excretion of formula fed infants was significantly higher compared to infants fed human milk, but did not differ between the two formula groups. Parameters of growth and milk tolerance did not differ between groups. Our results demonstrate that plasma LCP levels similar to those of breast fed infants can be achieved with the LCP supplemented formula used in this trial, without evidence of adverse effects of the LCP enrichment.